

RESEARCH ARTICLE

OPEN ACCESS

Comparative Study of Ofloxacin Accumulation in *M. smegmatis*, *M. kansasii*, and *M. tuberculosis*

Nirmala Deo^{1*} , Indu Singh^{2,3} , Krishnamurthy Venkatesan¹  and Divakar Sharma^{3*} 

¹Department of Biochemistry, National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Tajganj, Agra, Uttar Pradesh, India.

²School of Pharmacy, Graphic Era Hill University, Dehradun, Uttarakhand, India.

³Department of Biotechnology, Graphic Era Deemed to be University, Dehradun, Uttarakhand, India.

Abstract

Fluoroquinolones (FQs) manifest bactericidal activity in a concentration-dependent manner as they inhibit DNA gyrase and topoisomerase activity that are crucial in the replication process. They are the key component of a multidrug-resistant tuberculosis treatment regimen. FQs are effective against bacterial infections that cause skin, urinary tract, and prostate-related infections. Ofloxacin is also being tried as part of modified Multidrug Treatment (MDT) regimens against leprosy. This study examined the accumulation of ofloxacin in *M. smegmatis*, *M. kansasii*, and *M. tuberculosis*. These mycobacteria were grown in Sauton's liquid medium up to the exponential phase. Finally, cells were harvested, cleaned by washing, and resuspended. Suspensions were incubated with ofloxacin at 37 °C, and ofloxacin concentration in supernatants was observed using spectrofluorimetry. Ofloxacin concentrations were also observed in the absence or presence of Carbonyl cyanide *m*-chlorophenylhydrazine (CCCP), which is a proton motive force inhibitor. Steady state concentration (SSC) of ofloxacin was achieved in *M. smegmatis* (03 minutes), *M. kansasii* (03 minutes), and *M. tuberculosis* (05 minutes), and the ofloxacin accumulation level was 102 ng/mg, 100 ng/mg, and 107 ng/mg (dry weight of the bacilli), respectively. Ofloxacin accumulation was found at 10 µg/ml concentrations; however, CCCP addition was unable to influence the ofloxacin accumulation. This study concludes that ofloxacin accumulation is a simple diffusion in *M. smegmatis*, *M. kansasii*, and *M. tuberculosis*. Through simple diffusion, ofloxacin is transported across the mycobacterial cell envelope, inhibiting type II DNA isomerase (gyrase), which is required for DNA replication. Thus, it is effective in the treatment of disease.

Keywords: Mycobacteria, Ofloxacin, Fluoroquinolones (FQ), Carbonyl Cyanide *m*-chlorophenyl-hydrazine

*Correspondence: nirmaladeo2000@gmail.com; divakarsharma88@gmail.com

Citation: Deo N, Singh I, Venkatesan K, Sharma D. Comparative Study of Ofloxacin Accumulation in *M. smegmatis*, *M. kansasii*, and *M. tuberculosis*. J Pure Appl Microbiol. 2026;20(3):2214-2222. doi: 10.22207/JPAM.20.3.12

© The Author(s) 2026. **Open Access.** This article is distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

INTRODUCTION

The reduced permeation of antimicrobials through the cell wall of mycobacteria is crucial in antibiotic resistance in different mycobacterial species.¹⁻³ Rare antimicrobial agents are efficiently active against *Mycobacterium tuberculosis* as well as atypical mycobacteria (*Mycobacterium avium* complex). Tuberculosis (TB) is the foremost contributor to the high mortality rate worldwide. Only a few antimycobacterial agents are clinically active against *Mycobacterium tuberculosis*,⁴ which is frequently prescribed in the present era, specifically in combinations due to the emergence of multidrug-resistance (MDR). MDR is often viewed as a consequence of interrupted treatment of active TB during the longer course regimens, weak monitoring, poor patient compliance, healthcare facilities, and socioeconomic factors.^{5,6} For the bacterial dormancy or antibiotic-resistant phase, antibiotic pressure is also required. Fluoroquinolones (FQs) in combination are used clinically both as first and second-line treatment, and thus are considered valuable weapons against tuberculosis. Due to the higher potential and broad-spectrum activity of FQs, they are widely used as antibacterial drugs.⁷ FQs bind to DNA gyrase, topoisomerase II, and IV, leading to the inhibition of replication and transcription processes.⁸ *M. tuberculosis*, *M. bovis*, *M. leprae*, *M. marinum*, *M. kansasii*, and *M. xenopi* growth was repressed in vitro by ofloxacin/ciprofloxacin 0.5-2.0 mg/L concentrations.⁹⁻¹⁰ Broeck et al. reported the DNA gyrase structure of *E. coli* in the form of a nucleoprotein complex trapped by the gepotidacin antibiotic.¹¹ Disentanglement of the DNA-binding and cleavage domain leads to an enhanced insight into the enzyme complex's allosteric movements, which opens the avenue for targeting the conformational complexes or intermediates. As DNA gyrase is intracellular, FQs should reach inside the cell to exhibit the antibacterial effect. Therefore, permeability plays a crucial role in the FQs accumulation among the mycobacterial species.¹² Ofloxacin is extensively used as part of modified multidrug therapy regimens in the treatment of leprosy. A pilot study was done to check the accumulation of ofloxacin drug in *M. smegmatis*, *M. tuberculosis*,

and *M. kansasii* by fluorometry. *M. smegmatis* was considered a model organism because of its fast-growing nature and ability to produce homogeneous suspensions as compared to other species.¹³ The "TB Lipid Man", Minnikin, proposed a chemical model depicting structural elucidation of the cell envelope in mycobacteria, the presence of mycolic acid, a virulence factor,¹⁴ and applied it to studies of *M. smegmatis* and other mycobacteria.¹⁵ Furthermore, for exploring the mycobacterial genetics, *M. smegmatis* has been considered as a model strain.¹⁶ *M. kansasii* is a non-tuberculosis mycobacterium (NTM), a slow grower, and shows the clinical pattern of infection in six different ways, as in other mycobacterial species. *M. kansasii* infection usually causes chronic pulmonary cavitary disease, and due to this, initially, the patients are misdiagnosed with pulmonary tuberculosis.¹⁷ Apart from this, it also causes musculoskeletal infections, skin and soft tissue disease, lymphadenitis, sacroiliitis, skin lesions, and catheter-associated disease.¹⁸ TB is the biggest killer among infectious diseases despite the availability of the BCG vaccine and chemotherapy. Emergence of the drug-resistant *M. tuberculosis*, co-infection with HIV, and SARS-CoV-2, is still considered the biggest public health issue in the 21st century.¹⁹ An earlier study evaluated the different quinolone accumulation in other mycobacteria.²⁰ The present study aimed to speculate on the OFX accumulation in *M. smegmatis*, *M. kansasii*, and *M. tuberculosis* using fluorometric analysis.

MATERIALS AND METHODS

Antibiotics and chemicals

FQs (Ofloxacin, Sigma-Aldrich), carbonyl cyanide m-chlorophenyl-hydrazone (CCCP) were acquired from Merck (USA), 50 mM Sodium Phosphate Buffer (pH 7), and 0.1 M Glycine-HCl were procured from Merck (USA), and double-distilled water was purchased from Central Drug House (Delhi). Other chemicals were procured from local vendors.

Ethical consideration

The study deals with a mycobacterial strain, which has been taken from the repository

of our Institute. This study does not deal with human subjects; it is exempt from the human ethical committee.

Type of sampling and reasons for selection

Mycobacteria were used in this study. The reason for the selection of Mycobacteria for the study was that ofloxacin transports across the cell envelope through simple diffusion.

Inclusion criteria

To compare the accumulation of ofloxacin in non-tuberculous mycobacteria and tuberculous mycobacteria.

Exclusion criteria

Mycobacteria other than *M. tuberculosis*, which causes infection in humans, were excluded.

Bacterial strain

Standard strains of *Mycobacterium smegmatis* (ATCC-607), *Mycobacterium kansasii*, and *Mycobacterium tuberculosis*, which are sensitive to ofloxacin, were obtained from the

repository of ICMR- National JALMA Institute for Leprosy and Other Mycobacterial Diseases, India.

Ofloxacin accumulation in *M. kansasii*, *M. tuberculosis*, and *M. smegmatis*

M. kansasii, *M. tuberculosis*, and *M. smegmatis* were cultured separately in Sauton's liquid medium until the exponential phase. Cell pellets, centrifuged and suspended in buffer (0.1 M phosphate buffer, pH 7.2, O.D. of 0.4-0.5) and incubated in the presence of ofloxacin (10 µg/ml) at 37 °C. One ml of each aliquot was taken at various time intervals (minutes) for twenty minutes, and centrifuged, the ofloxacin concentration was tested in the supernatants using spectrofluorimetry. A similar set of experiments was also done with Carbonyl cyanide m-chlorophenylhydrazone (CCCP), at 100 µM, 10 minutes before and after ofloxacin addition.²¹

Dry cell weight

To proceed with every set of experiments, 1 mL aliquots of each *M. smegmatis*, *M. kansasii*,




Figure 1. Accumulation of ofloxacin (OFX) in *M. smegmatis* and *M. kansasii* without and with CCCP (ng/mg dry cell weight; *Mean of 3 values)

Table 1. Accumulation of ofloxacin (OFX) in *M. smegmatis* and *M. kansasii* without and with CCCP (ng/mg dry cell weight; *Mean of 3 values)

Time (Minutes)	<i>M. smegmatis</i> OFX	<i>M. smegmatis</i> OFX + CCCP	<i>M. kansasii</i> OFX	<i>M. kansasii</i> OFX + CCCP
0	0	0	0	0
1	96	101	95	100
3	102	103	105	101
5	103	105	102	103
7	106	104	105	101
9	104	99	100	95
11	103	104	95	98
13	104	98	94	93
15	98	99	98	95
20	99	101	100	90

and *M. tuberculosis* suspension were taken in 1.5 mL tubes separately. Then, cells were centrifuged at 3000 x g for 15 minutes at 4 °C. The cell pellet was again washed with HPLC-grade water (10 mL) and then centrifuged at 3003 x g for 15 minutes at 4 °C. Finally, all pellets were air-dried at 60 °C for approximately twelve hours, and weights were calculated. All the tests were performed in triplicate.

RESULTS

Ofloxacin accumulation

The method employed to determine ofloxacin accumulation was initially developed by Williams et al. for norfloxacin accumulation in *M. aurum* and *M. smegmatis*.²¹ To achieve a better fluorescence, the optimum concentration was set at 10 µg/ml for accumulation studies. The ofloxacin accumulation kinetics for *M. smegmatis* and *M.*


**Figure 2.** Accumulation of ofloxacin (OFX) in *M. tuberculosis* without and with CCCP (ng/mg dry cell weight; *Mean of 3 values)

Table 2. Accumulation of ofloxacin (OFX) in *M. tuberculosis* without and with CCCP (ng/mg dry cell weight; *Mean of 3 values)

Time (Minutes)	<i>M. tuberculosis</i> OFX	<i>M. tuberculosis</i> OFX + CCCP
0	0	0
0.5	95	98
1	112	108
1.5	107	114
2	115	111
2.5	116	110
3	121	115
3.5	118	118
4	115	120
4.5	119	122

kansasii have been shown (Figure 1) and (Table 1). The accumulation kinetics in *M. tuberculosis* are tabulated in Table 2 and shown in Figure 2.

Steady State Concentration (SSC) of ofloxacin in *M. smegmatis* was achieved within 3 minutes, and the ofloxacin accumulation level was 102 ng/mg of the bacilli dry weight. For *M. kansasii* and *M. tuberculosis*, the time span for SSC was 5 minutes, and the levels of ofloxacin accumulation were 100 ng/mg and 107 ng/mg, respectively. The accumulated ofloxacin concentration was approximately 10 µg/ml of exposed concentrations, which indicated that CCCP was unable to influence the ofloxacin accumulation. The addition of 100 µM CCCP for 10 minutes before the drug exposure did not influence the accumulation kinetics.

DISCUSSION

FQs belong to the family of broad-spectrum antibiotics, are greatly effective towards Gram-negative bacteria, and tremendously impart bactericidal action.²²⁻²⁵ Bove et al.²⁶ mentioned that due to their broad-spectrum activity of FQs and their physicochemical properties are mostly used as antimicrobials in human and animal medicine, which has led to great attraction in clinical situations.^{24,26} Over the last two decades, FQs have become popular due to their promising group of antimicrobial agents to treat the infection caused by MDR bacterial strains, such as aminoglycosides, β-lactam, and macrolide-resistant microbes.^{26,27}

The addition of a fluorine atom to nalidixic acid leads to the derivation of FQs. Due to this, the activity against bacteria increases and leads to improved absorption, metabolism, and excretion, including high tissue and intracellular distribution.²⁸⁻³⁰ Compared to other groups of antibacterial agents, FQs are more effective at lower concentrations.

Against most of the susceptible microbes, FQs' minimum inhibitory concentrations (MICs) range from 0.001-1.0 µg/ml,²⁵ which was due to the prolonged post-antibiotic effect. Molecularly, Intracellular enzymes such as DNA gyrase and topoisomerase IV are the major targets of FQs. While in the microbe, FQs enter via pores and quickly accumulate with specific steady state concentrations.^{31,32} The enzyme-DNA complex was stabilized by FQs' covalent binding, where the DNA is usually cleaved into two strands.³³ The binding is in a cooperative manner by DNA gyrase with the help of electrostatic binding. This proposes the binding kinetics of FQs, which can fit into the deep pocket and lead to gyrase inhibition.³⁴ Type II isomerase unwinds, cuts, and consecutively reseals the DNA; however, FQs inhibit the resealing and lead to fragment generation, which are later destroyed by exonucleases.^{35,36} FQs' resistance does not emerge quickly because it is usually due to a mutation in the intrinsic genes of microbes, and it is rarely reported in plasmids.²³ Plasmid-mediated FQs resistance has not been documented.³⁷

In vitro and in vivo studies showed FQs as potent anti-mycobacterial agents.^{38,39} There is a tremendous effort to inculcate the FQs into frontline antibiotics like ofloxacin, moxifloxacin, and ciprofloxacin.⁴⁰⁻⁴³ Industrial efforts have also been seen in the discovery and development of newer FQs, which might have potential in TB treatment. However, FQs' selection for TB treatment is based on their efficacy in murine models; therefore, few FQs are tested in these murine models. The cell wall of mycobacteria comprises 60% of lipids by dry weight, giving it extreme hydrophobicity, and has been used in chemotaxonomy and pathogenesis.⁴⁴⁻⁴⁶ For maintaining cellular integrity and virulence, *M. tuberculosis* has a special structure of cell envelope (peptidoglycan layer) and composition.⁴⁷

Jacobo-Delgado explored the convolution of the *M. tuberculosis* cell wall and analyzed the antimicrobial peptides' efficacy to clear the bacilli.⁴⁸ In *M. chelonae*, permeability for β -lactams is three times less than *E. coli* and 10-times higher than *P. aeruginosa*.¹ FQs are usually hydrophobic, and passive diffusion via lipid bilayer or porin is the existing mechanism in Gram-negative bacteria⁴⁹; however, in bacteria (Gram-positive), it is simply diffusion across the membrane.⁵⁰ Due to the hydrophilic nature of norfloxacin, its accumulation was non-saturable in *M. aurum* up to the 0-100 mg/ml concentration range, and its transportation was not affected in CCCP presence.⁵¹ Therefore, they suggested that noroxacin is transported through a non-saturable porin pathway. Porin efficiency in *M. smegmatis* and *M. chelonae* was lower than that of other bacterial porins.^{52,53} Ofloxacin is a broader-spectrum analog of norfloxacin, a second-generation fluoroquinolone, and its uptake could be due to the amino acid transporter.⁵⁴ Newer generation FQs have an extended spectrum and improved activity against mycobacteria and other bacteria compared to older generation FQs. For ofloxacin accumulation, the cell wall does not serve as a barrier.

Earlier, Deo et al. reported the level of OFX, NFX, LFX, and CFX accumulation in *M. smegmatis* by simple diffusion.⁵⁵ The SSC observed in the present study is similar to NFX-SSCs in *M. smegmatis* mc2155, as shown in Liu et al.⁵⁶ Another previous report showed that the SSC of NFX was 35 ng/mg for *M. smegmatis* (strain CNCM 7326). Kocagoz et al.⁵⁷ also found that NFX-SSC was 110 pmol/mg of cells (35 ng/mg of cells) for avirulent strain *M. tuberculosis*, which suggests that NFX is less permeable compared to other mycobacteria.^{58,59} The present study shows the OFX accumulation in *M. smegmatis*, *M. kansasii*, and *M. tuberculosis*. The SSC of OFX in *M. smegmatis* was 3 minutes, and the 102 ng/mg dry weight was the level of accumulation level. In *M. kansasii*, SSC time was five minutes, and 100 ng/mg was the accumulation level; however, in *M. tuberculosis*, SSC was 107 ng/mg in five minutes. The permeability of mycobacteria to ofloxacin varies between mycobacterial species.

CONCLUSION

In this study, the transportation of ofloxacin across the cell envelopes of *M. smegmatis*, *M. tuberculosis*, and *M. kansasii* was studied by diffusion. The intracellular level of drug in the presence of CCCP inhibitor was not affected, which suggests that FQs are transported by other means, not by efflux pumps, in these mycobacterial drug-susceptible clinical isolates. For validation, more studies are needed with FQ-resistant clinical isolates.

ACKNOWLEDGMENTS

The authors are grateful to the Director, ICMR-NJIL, and OMD for the support. This research was supported by ICMR, New Delhi. The authors are also thankful to the staff of the Biochemistry Division. The authors wish to acknowledge the invaluable contributions of Dr. Nirmala Deo to this study. Dr. Deo, who served as the first and co-corresponding author of this manuscript, sadly passed away in March 2026. We dedicate this work to her memory and her enduring contributions to science.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHORS' CONTRIBUTION

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

None.

DATA AVAILABILITY

All datasets generated or analyzed during this study are included in the manuscript.

ETHICS STATEMENT

Not applicable.

REFERENCES

1. Brennan PJ, Nikaido H. The envelope of mycobacteria. *Ann Rev Biochemi.* 1995;64(1):29-63. doi: 10.1146/annurev.bi.64.070195.000333

2. Jarlier V, Nikaido H. Permeability barrier to hydrophilic solutes in *Mycobacterium chelonae*. *J Bacteriol*. 1990;172(3):1418-23. doi: 10.1128/jb.172.3.1418-1423.1990
3. Jarlier V, Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. *FEMS Microbiol Lett*. 1994;123(1-2):11-18. doi: 10.1111/j.1574-6968.1994.tb07194.x
4. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against *Mycobacterium tuberculosis*: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. *Antimicrob Agents Chemother*. 2007;51(2):576-582. doi: 10.1128/AAC.00414-06
5. Wanger A, Chavez V, Huang RS, Wahed A, Actor JK, Dasgupta A. Antibiotics, antimicrobial resistance, antibiotic susceptibility testing, and therapeutic drug monitoring for selected drugs. *Microbiol Mol Diagn Pathol*. 2017;119-153. doi: 10.1016/b978-0-12-805351-5.00007-7
6. Goshiye SM, Dube L, Mogas SB, Marine BT. Predictive Factors Associated With Multidrug Resistant Tuberculosis Among Tuberculosis Patients in Southwest Ethiopia: An Unmatched Case Control Study. *Health Sci Rep*. 2025;8(11):e71408. doi: 10.1002/hsr2.71408
7. Pais JP, Policarpo M, Pires D, et al. Fluoroquinolone derivatives in the treatment of *Mycobacterium tuberculosis* infection. *Pharmaceuticals*. 2022;15(10):1213. doi: 10.3390/ph15101213
8. Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. *Cold Spring Harb Perspect Med*. 2016;6(9):a025320. doi: 10.1101/cshperspect.a025320
9. Leysen DC, Haemers A, Pattyn SR. Mycobacteria and the new quinolones. *Antimicrob Agents Chemother*. 1989;33(1):1-5. doi: 10.1128/AAC.33.1.1
10. Garcia-Rodriguez JA, Garcia AG. In-vitro activities of quinolones against mycobacteria. *J Antimicrob Chemother*. 1993;32(6):797-808. doi: 10.1093/jac/32.6.797
11. Vanden Broeck A, Lotz C, Ortiz J, Lamour V. Cryo-EM structure of the complete *E. coli* DNA gyrase nucleoprotein complex. *Nat Commun*. 2019;10(1):4935. doi: 10.1038/s41467-019-12914-y
12. Piddock LJV, Ricci V. Accumulation of five fluoroquinolones by *Mycobacterium tuberculosis* H37Rv. *J Antimicrob Chemother*. 2001;48(6):787-91. doi: 10.1093/jac/48.6.787
13. Chantefort A, Lellouche M. Bactericidal efficacy of a disinfectant by AFNOR standards NF T 72-150 and NF T 72-151. A collaborative study. *Pathol Bio (Paris)*. 1984;32(5 Pt 2):623-627. PMID: 6431382.
14. Lee OY, Wu HH, Besra GS. Professor David Minnikin Memorial Lecture: An era of the mycobacterial cell wall lipid biomarkers. *Tuberculosis*. 2023;1(143):102415. doi: 10.1016/j.tube.2023.102415
15. Minnikin DE. Chemical principles in the organization of lipid components in the mycobacterial cell envelope. *Res Microbiol*. 1991;142(4):423-427. doi: 10.1016/0923-2508(91)90114-p
16. Revel V, Cambau E, Jarlier V, Sougakoff W. Characterization of mutations in *Mycobacterium smegmatis* involved in resistance to fluoroquinolones. *Antimicrob Agents Chemother*. 1994;38(9):1991-6. doi: 10.1128/AAC.38.9.1991
17. Machineni NVK, Gullapalli D, Tangutoori S, et al. Dust to disease: cavitary lung lesion with *Mycobacterium kansasii* in a black lung patient. *J Investig Med High Impact Case Rep*. 2025;13:23247096251348906. doi: 10.1177/23247096251348906
18. Andalibi F, Bostanghadiri N, Amirzafarani N, Irajian G, Mirkalantari S. Efficacy and treatment outcome of infected patients with pulmonary *Mycobacterium kansasii*: A systematic review. *J Clin Tuberc Other Mycobact Dis*. 2024;1(36):100463. doi: 10.1016/j.jctube.2024.100463
19. Yang J, Zhang L, Qiao W, Luo Y. *Mycobacterium tuberculosis*: Pathogenesis and therapeutic targets. *MedComm*. 2023;4(5):e353. doi: 10.1002/mco2.353
20. Corti S, Chevalier J, Cremieux A. Intracellular accumulation of norfloxacin in *Mycobacterium smegmatis*. *Antimicrob Agents and Chemother*. 1995;39(11):2466-2471. doi: 10.1128/AAC.39.11.2466
21. Williams KJ, Chung GAC, Piddock LJV. Accumulation of norfloxacin by *Mycobacterium aurum* and *Mycobacterium smegmatis*. *Antimicrob Agents Chemother*. 1998;42(4):795-800. doi: 10.1128/AAC.42.4.795
22. European Medicines Agency. Fluoroquinolone Antibiotics: Reminder of Measures to Reduce the Risk of Long-Lasting, Disabling and Potentially Irreversible Side Effects. 2023. <https://www.ema.europa.eu/en/news/fluoroquinolone-antibiotics-reminder-measures-reduce-risk-long-lasting-disabling-potentially-irreversible-side-effects>. (accessed 28 July 2023).
23. Brown SA, Cooper J, Gauze JJ, Greco DS, Weise DW, Buck JM. Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. *Am J Vet Res*. 1990;51(7):1065-1070. doi: 10.2460/ajvr.1990.51.07.1065
24. Petri WA. Sulfonamides, trimethoprim, sulfamethoxazole, quinolones, and agents for urinary tract infections. *Goodman & Gilman's the Pharmacological Basis of Therapeutics*. New York (NY): McGraw-Hill. 2006:1111-25.
25. McKellar Q, Gibson I, Monteiro A, Bregante M. Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. *Antimicrob agents chemother*. 1999; 43(8): 1988-1992. doi: 10.1128/aac.43.8.1988
26. Bove C, Baldock RA, Champigneulle O, Martin L, Bennett CL. Fluoroquinolones: old drugs, putative new toxicities. *Expert Opin Drug Safety*. 2022;21(11):1365-1378. doi: 10.1080/14740338.2022.2147924
27. Rodrigues CF, Silva F. The rise, fall, and rethink of (Fluoro) quinolones: A quick rundown. *Pathogens*. 2025;14(6):525. doi: 10.3390/pathogens14060525

28. Pascual A, Garcia I, Ballesta S, Perea EJ. Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells. *Antimicrob Agents Chemother.* 1997;41(2):274-277. doi: 10.1128/aac.41.2.274
29. Ito T, Yano I, Masuda S, Hashimoto Y, Inui KI. Distribution characteristics of levofloxacin and grepafloxacin in rat kidney. *Pharm Res.* 1999;16(4):534-539. doi: 10.1023/A:1018871029244
30. Ezelarab HAA, Abbas SH, Hassan HA, Abuo Rahma GE. Recent updates of fluoroquinolones as antibacterial agents. *Archiv der Pharmazie.* 2018;351(9):1800141. doi: 10.1002/ardp.201800141
31. Chapman JS, Georgopapadakou NH. Routes of quinolone permeation in *Escherichia coli*. *Antimicrob Agents Chemother.* 1988;32(4):438-442. doi: 10.1128/AAC.32.4.438
32. Piddock LJ. New quinolones and gram-positive bacteria. *Antimicrob Agents Chemother.* 1994;38(2):163-9. doi: 10.1128/aac.38.2.163
33. Bush NG, Diez-Santos I, Abbott LR, Maxwell A. Quinolones: mechanism, lethality and their contributions to antibiotic resistance. *Molecules.* 2020;25(23):5662. doi: 10.3390/molecules25235662
34. Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. *Antimicrob Agents Chemother.* 1985;28(4):581-586. doi: 10.1128/AAC.28.4.581
35. Bourguignon GJ, Levitt M, Sternglanz R. Studies on the mechanism of action of nalidixic acid. *Antimicrob Agents Chemother.* 1973;4(4):479-486. doi: 10.1128/AAC.4.4.479
36. Shen LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. *Proc Natl Acad Sci USA.* 1985;82(2):307-311. doi: 10.1073/pnas.82.2.307
37. Dowling PM, Baptiste KE. Miscellaneous antimicrobials: ionophores, nitrofurans, nitroimidazoles, rifamycins, and others. In: Dowling PM, Prescott JF, Baptiste KE, eds. *Antimicrobial Therapy in Veterinary Medicine*. 6th ed. Wiley Blackwell; 2025. Chapter 18. doi: 10.1002/9781119654629.ch18
38. Lowther J, Bryskier A. Fluoroquinolones and tuberculosis. *Expert Opin Investig Drugs.* 2002;11(2):233-258. doi: 10.1517/13543784.11.2.233
39. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. *Lancet Infect Dis.* 2003;3(7):432-442. doi: 10.1016/S1473-3099(03)00671-6
40. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. *Am J Respirat Crit Care Med.* 2004;169(3):421-426. doi: 10.1164/rccm.200310-1380OC
41. Narayanan P. Tuberculosis Research Centre. Shortening short course chemotherapy a randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. *Ind J Tub.* 2002;49:27-38.
42. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. *Antimicrob Agents Chemother.* 2002;46(6):1875-1879. doi: 10.1128/aac.46.6.1875-1879.2002
43. Falzon D, Schunemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. *Eur Respirat J.* 2017;49(3):1602308. doi: 10.1183/13993003.02308-2016
44. Jackson M. The mycobacterial cell envelope—lipids. *Cold Spring Harb Perspect Med.* 2014;4(10):a021105. doi: 10.1101/cshperspect.a021105
45. Singh P, Rameshwaram NR, Ghosh S, Mukhopadhyay S. Cell envelope lipids in the pathophysiology of *Mycobacterium tuberculosis*. *Future Microbiol.* 2018;13(6):689-710. doi: 10.2217/fmb-2017-0135
46. Ghazaei C. *Mycobacterium tuberculosis* and lipids: Insights into molecular mechanisms from persistence to virulence. *J Res Med Sci.* 2018;23(1):63. doi: 10.4103/jrms.JRMS_904_17
47. Maitra A, Munshi T, Healy J, et al. Cell wall peptidoglycan in *Mycobacterium tuberculosis*: An Achilles' heel for the TB-causing pathogen. *FEMS Microbiol Rev.* 2019;43(5):548-75. doi: 10.1093/femsre/fuz016
48. Jacobo-Delgado YM, Rodriguez-Carlos A, Serrano CJ, Rivas-Santiago B. *Mycobacterium tuberculosis* cell-wall and antimicrobial peptides: a mission impossible? *Front Immunol.* 2023;14:1194923. doi: 10.3389/fimmu.2023.1194923
49. Piddock LJV. Mechanism of quinolone uptake into bacterial cells. *J Antimicrob Chemother.* 1991;27(4):399-403. doi: 10.1093/jac/27.4.399
50. Furet YX, Deshusses J, Pechere JC. Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 1992;36(11):2506-2511. doi: 10.1128/aac.36.11.2506
51. Asuquo AE, Piddock LJV. Accumulation and killing kinetics of fifteen quinolones for *Escherichia coli*, *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *J Antimicrob Chemother.* 1993;31(6):865-880. doi: 10.1093/jac/31.6.865
52. Trias J, Jarlier V, Benz R. Porins in the cell wall of mycobacteria. *Science.* 1992;258(5087):1479-81. doi: 10.1126/science.1279810
53. Trias J, Benz R. Characterization of the channel formed by the mycobacterial porin in lipid bilayer membranes. Demonstration of voltage gating and of negative point charges at the channel mouth. *J Biol Chem.* 1993;268(9):6234-6240. doi: 10.1016/S0021-9258(18)53244-0
54. Pascual A, Garcia I, Perea EJ. Fluorometric measurement of ofloxacin uptake by human polymorphonuclear leukocytes. *Antimicrob Agents Chemother.* 1989;33(5):653-656. doi: 10.1128/aac.33.5.653
55. Deo N, Sharma D, Bisht D, Venkatesan K. Evaluation of the intracellular accumulation of fluoroquinolones in mycobacteria by fluorometric assays. *Int J*

- Mycobacteriol.* 2020;9(1):34-38. doi: 10.4103/ijmy.ijmy_194_19
56. Liu J, Takiff HE, Nikaido H. Active efflux of fluoroquinolones in *Mycobacterium smegmatis* mediated by LfrA, a multidrug efflux pump. *J Bacteriol.* 1996;178(13):3791-5. doi: 10.1128/jb.178.13.3791-3795.1996
57. Kocagoz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of *Mycobacterium tuberculosis* H37Ra. *Antimicrob Agents Chemother.* 1996;40(8):1768-74. doi: 10.1128/aac.40.8.1768
58. Woo SR, Sotos J, Hart AP, Barletta RG, Czuprynski CJ. Bovine monocytes and a macrophage cell line differ in their ability to phagocytose and support the intracellular survival of *Mycobacterium avium* subsp. *paratuberculosis*. *Vet Immunol Immunopathol.* 2006;110(1-2):109-120. doi: 10.1016/j.vetimm.2005.09.010
59. Vacher S, Pellegrin JL, Leblanc F, Fourche J, Maugein J. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin, and grepafloxacin. *J Antimicrob Chemother.* 1999;44(5):647-652. doi: 10.1093/jac/44.5.647